Huang, Po-Han Yu, Jen Chu, Yin-Yi Lin, Yang-Hsiang Yeh, Chau-Ting
Published in
Journal of clinical medicine
Patients with advanced hepatocellular carcinoma (HCC) are treated by immunotherapy and/or targeted agents, such as sorafenib. Several single nucleotide polymorphisms (SNPs) and clinical scores have been proposed as prognostic markers in HCC patients treated with sorafenib. This study aimed to validate the prognostic values of these markers in a ter...
Noguchi, Hirotsugu Higashi, Michiyo Desaki, Ryo Tasaki, Takashi Kirishima, Mari Kitazono, Ikumi Tabata, Kazuhiro Tanimoto, Akihide
Published in
International journal of surgical pathology
Extramedullary hematopoiesis (EMH) in adults usually occurs in the liver, spleen, and lymph nodes when bone marrow hematopoiesis fails. EMH has also been recognized in benign or malignant hepatic tumors, such as hepatoblastoma, hepatocellular adenoma, and vascular tumors. However, it is rarely encountered in hepatocellular carcinoma (HCC) in elderl...
Yang, Che-Jui Wu, Meng-Hsuan Tsai, Jai-Jen Hsu, Fei-Ting Hsia, Te-Chun Liu, Kuo-Ching Kuo, Yu-Cheng
Published in
Anticancer research
AKT/ERK signaling transduction and anti-apoptosis effects have both been recognized as important mediators of hepatocellular carcinoma (HCC) progression. Targeting AKT/ERK signaling and mediating apoptosis may be beneficial for alleviating HCC growth. Lenvatinib, a tyrosine kinase inhibitor, has been approved by the FDA to treat HCC since 2018 as a...
Sun, Jiazeng Wu, Guanhui Pastor, Florentin Rahman, Naimur Wang, Wen-Hung Zhang, Zhengtao Merle, Philippe Hui, Lijian Salvetti, Anna Durantel, David
...
Published in
Gut
RNA helicase DDX5 is downregulated during HBV replication and poor prognosis HBV-related hepatocellular carcinoma (HCC). The objective of this study is to investigate the role of DDX5 in interferon (IFN) signalling. We provide evidence of a novel mechanism involving DDX5 that enables translation of transcription factor STAT1 mediating the IFN respo...
Hyun Sung, Ji Sakamori, Ryotaro Yamada, Ryoko Yoshioka, Teppei Sakane, Sadatsugu Tahata, Yuki Shigekawa, Minoru Kodama, Takahiro Hikita, Hayato Tatsumi, Tomohide
...
Published in
Internal medicine (Tokyo, Japan)
We herein report a 34-year-old woman born with tetralogy of Fallot who had undergone 5 cardiac repair procedures. She developed liver nodules with congestive cirrhosis secondary to severe mitral regurgitation and an atrial septal defect. A percutaneous liver biopsy showed hepatocellular carcinoma with liver fibrosis, which was treated using transar...
Shi, Wen-Kai Shang, Qiao-Li Zhao, Yong-Fu
Published in
Oncology reports
Hepatocellular carcinoma (HCC) is a malignant tumor with a high metastatic rate. Recent studies have shown that the mitosis‑associated spindle‑assembly checkpoint regulatory protein spindle pole body component 25 homolog (SPC25) promotes HCC progression, although the underlying mechanism has yet to be fully elucidated. The aim of the present study ...
Tang, Maomao Huang, Yuzhe Liang, Xiao Tao, Yaotian He, Ning Li, Zhenbao Guo, Jian Gui, Shuangying
Published in
AAPS PharmSciTech
Multidrug resistance (MDR) is a key determinant for hepatocellular carcinoma chemotherapy failure. P-glycoprotein is one of the main causes of MDR by causing drug efflux in tumor cells. In order to solve this thorny problem, we prepared a sorafenib-loaded polylactic acid-glycolic acid (PLGA) - D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS...
Fang, Fang Qiu, Bin Zhen, Peng Wang, Junjie
Published in
Frontiers in Oncology
Background Hypofractionated radiotherapy delivered for portal vein tumor thrombosis (PVTT) located in the main portal vein is rarely exploited. The study aimed to evaluate the efficacy and safety of hypofractionated radiotherapy as palliative treatment for PVTT in cirrhotic patients with hepatocellular carcinoma. Methods From March 2016 to July 202...
Cao, Xinyi Meng, Peiyi Shao, Yuyin Yan, Guoquan Yao, Jun Zhou, Xinwen Liu, Chao Zhang, Lei Shu, Hong Lu, Haojie
...
Published in
Frontiers in Molecular Biosciences
Glycosylation inhibition has great potential in cancer treatment. However, the corresponding cellular response, protein expression and glycosylation changes remain unclear. As a cell-permeable small-molecule inhibitor with reduced cellular toxicity, N-linked glycosylation inhibitor-1 (NGI-1) has become a great approach to regulate glycosylation in ...
Wu, Zeng-Hong Li, Cheng Zhang, You-Jing Lin, Rong
Published in
Frontiers in Cell and Developmental Biology
Background: Hepatocellular carcinoma (HCC) is one of the fifty most common cancers globally, having a high mortality rate being the second most common cause of cancer-related deaths. However, little attention has been paid to the involvement of exosomes and ceRNA in HCC. Method: The study aimed to explore exosome data from exoRBase database and a f...
